Literature DB >> 19177017

Single-vector inducible lentiviral RNAi system for oncology target validation.

Dmitri Wiederschain1, Susan Wee, Lin Chen, Alice Loo, Guizhi Yang, Alan Huang, Yan Chen, Giordano Caponigro, Yung-Mae Yao, Christoph Lengauer, William R Sellers, John D Benson.   

Abstract

The use of RNA interference (RNAi) has enabled loss-of-function studies in mammalian cancer cells and has hence become critical for identifying and validating cancer drug targets. Current transient siRNA and stable shRNA systems, however, have limited utility in accurately assessing the cancer dependency due to their short-lived effects and limited in vivo utility, respectively. In this study, a single-vector lentiviral, Tet-inducible shRNA system (pLKO-Tet-On) was generated to allow for the rapid generation of multiple stable cell lines with regulatable shRNA expression. We demonstrate the advantages and versatility of this system by targeting two polycomb group proteins, Bmi-1 and Mel-18, in a number of cancer cell lines. Our data show that pLKO-Tet-On-mediated knockdown is tightly regulated by the inducer tetracycline and its derivative, doxycycline, in a concentration- and time-dependent manner. Furthermore, target gene expression is fully restored upon withdrawal of the inducing agent. An additional, 17 distinct gene products have been targeted by inducible shRNAs with robust regulation in all cases. Importantly, we functionally validate the ability of the pLKO-Tet-On vector to reversibly silence targeted transcripts in vivo. The versatile and robust inducible lentiviral RNAi system reported herein can therefore serve as a powerful tool to rapidly reveal tumor cell dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19177017     DOI: 10.4161/cc.8.3.7701

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  217 in total

1.  Novel lentiviral-inducible transgene expression systems and versatile single-plasmid reporters for in vitro and in vivo cancer biology studies.

Authors:  W H Shuen; R Kan; Z Yu; H L Lung; M L Lung
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 2.  A primer on using pooled shRNA libraries for functional genomic screens.

Authors:  Guang Hu; Ji Luo
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2012-02       Impact factor: 3.848

3.  Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase.

Authors:  Dana M Gwinn; Alex G Lee; Marcela Briones-Martin-Del-Campo; Crystal S Conn; David R Simpson; Anna I Scott; Anthony Le; Tina M Cowan; Davide Ruggero; E Alejandro Sweet-Cordero
Journal:  Cancer Cell       Date:  2018-01-08       Impact factor: 31.743

4.  Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner.

Authors:  Tejas S Tirodkar; Ping Lu; Aiping Bai; Matthew J Scheffel; Salih Gencer; Elizabeth Garrett-Mayer; Alicja Bielawska; Besim Ogretmen; Christina Voelkel-Johnson
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

5.  ZNF365 promotes stalled replication forks recovery to maintain genome stability.

Authors:  Yuqing Zhang; Eunmi Park; Christopher S Kim; Ji-hye Paik
Journal:  Cell Cycle       Date:  2013-08-06       Impact factor: 4.534

6.  Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

Authors:  Nikita S Sharma; Vineet K Gupta; Vanessa T Garrido; Roey Hadad; Brittany C Durden; Kousik Kesh; Bhuwan Giri; Anthony Ferrantella; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

7.  Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells.

Authors:  Saskia M Brachmann; Irmgard Hofmann; Christian Schnell; Christine Fritsch; Susan Wee; Heidi Lane; Shaowen Wang; Carlos Garcia-Echeverria; Sauveur-Michel Maira
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-10       Impact factor: 11.205

8.  Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival.

Authors:  Yubao Wang; Michael Begley; Qing Li; Hai-Tsang Huang; Ana Lako; Michael J Eck; Nathanael S Gray; Timothy J Mitchison; Lewis C Cantley; Jean J Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

9.  Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.

Authors:  Mari Gasparyan; Miao-Chia Lo; Hui Jiang; Chang-Ching Lin; Duxin Sun
Journal:  J Biol Chem       Date:  2020-05-28       Impact factor: 5.157

10.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.